Rossari Biotech Limited, a leading specialty chemicals manufacturer in India, has announced a strong financial performance for the fourth quarter (Q4) and full financial year FY26, showcasing robust growth across key metrics. The company reported a 34% year-on-year (YoY) increase in profit after tax (PAT) for Q4 FY26, driven by healthy demand across segments and effective business execution.

The results underline the company’s ability to navigate a mixed global environment while maintaining growth momentum through its diversified product portfolio and strong operational capabilities.

Q4 FY26 Performance Highlights

Rossari Biotech delivered its highest-ever quarterly performance in Q4 FY26, with strong growth in revenue and profitability.

Key financial highlights include:

• Revenue from operations increased by 18% to ₹684.9 crore, compared to ₹579.6 crore in Q4 FY25
• EBITDA rose by 11% to ₹77.3 crore from ₹69.5 crore
• EBITDA margin stood at 11.3%, slightly lower than 12.0% last year
• Profit After Tax (PAT surged 34%) to ₹46.0 crore from ₹34.4 crore
• Diluted EPS increased to ₹8.29, compared to ₹6.21

This performance reflects strong demand across all major segments and improved operational efficiency.

FY26 Full-Year Financial Performance

For the full financial year FY26, Rossari Biotech continued its growth trajectory:

• Revenue increased by 15% to ₹2,396.4 crore from ₹2,080.3 crore
• EBITDA grew by 8% to ₹286.0 crore from ₹265.1 crore
• EBITDA margin stood at 11.9%, compared to 12.7% in FY25
• PAT increased by 9% to ₹149.2 crore from ₹136.4 crore
• EPS rose to ₹26.93 from ₹24.63

The steady performance indicates consistent growth across business cycles, supported by strong demand and strategic initiatives.

Segment-Wise Growth Performance

Rossari operates across three key segments:

• Home, Personal Care and Performance Chemicals (HPPC)
• Textile Specialty Chemicals (TSC)
• Animal Health and Nutrition (AHN)

All three segments reported healthy double-digit growth in Q4 FY26, highlighting:

• Strong demand across industries
• Effective product positioning
• Ability to cater to diverse end-user applications

This diversified presence has helped the company mitigate risks and maintain stability.

Management Commentary and Strategic Insights

The company’s leadership, including Promoter & Executive Chairman Edward Menezes and Managing Director Sunil Chari, expressed confidence in the company’s performance and future outlook.

They highlighted that:

• Q4 marked the highest-ever quarterly revenue and EBITDA
• The company successfully navigated a volatile global environment, including geopolitical challenges
• Growth was supported by strong execution and diversified operations

However, they also pointed out that:

• Margins were impacted due to rising raw material costs
• There was a lag in passing on cost inflation to customers

To address this, the company is focusing on:

• Calibrated pricing strategies
• Improving product mix
• Enhancing operating leverage

These steps are expected to support margin recovery in the coming periods.

Capacity Expansion and Capex Plans

A major highlight of the quarter was the expansion of manufacturing capacity.

• Unitop commissioned an additional 15,000 MTPA ethoxylation capacity at its Dahej facility
• Total installed capacity now stands at 66,000 MTPA

This expansion strengthens the company’s ability to:

• Meet growing demand
• Improve production efficiency
• Enhance market competitiveness

Additionally, the company has rephased its capex plans over the next two years, aligning investments with evolving market conditions while maintaining strategic goals.

Focus on Innovation and R&D

Rossari Biotech continues to invest heavily in research and development (R&D) to drive innovation.

Key developments include:

• Establishment of a new R&D facility in Navi Mumbai
• Relocation and expansion of its existing R&D centre from IIT Bombay

This move is expected to:

• Accelerate innovation cycles
• Strengthen the company’s competitive edge
• Enable development of advanced and customised solutions

R&D remains a core pillar of Rossari’s long-term growth strategy.

Dividend Announcement

The Board of Directors has recommended a dividend of ₹0.50 per share for FY26.

This reflects:

• The company’s financial stability
• Commitment to shareholder returns
• Confidence in future growth

Board Changes and Governance

The company also announced the appointment of Mr. Udeypaul Singh Gill as an Additional Director, designated as a Non-Executive Independent Director.

This move strengthens:

• Corporate governance framework
• Board oversight and independence
• Strategic decision-making

Industry Outlook and Challenges

The specialty chemicals sector in India continues to benefit from:

• Growing demand from FMCG, textiles, and industrial sectors
• Increasing focus on sustainable and customised solutions
• Shift in global supply chains towards India

However, challenges remain, including:

• Volatility in raw material prices
• Impact of global geopolitical tensions
• Pressure on profit margins

Rossari’s diversified portfolio and strategic approach position it well to navigate these challenges.

Future Growth Strategy

Looking ahead, Rossari Biotech plans to focus on:

• Disciplined execution
• Customer-centric innovation
• Expansion of manufacturing capabilities
• Strengthening market presence

The company aims to build an integrated and intelligent specialty chemicals platform, delivering long-term value for stakeholders.

Join our Telegram Channel for Latest News and Regular Updates.

Start your Mutual Fund Journey  by Opening Free Account in Asset Plus.